Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PHGDH | O43175 | 9/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13151484 | 1.00 | RXFP1 (0.52) | RXFP1AHRMEN1KMT2APHGDH | |
| SCHEMBL47199 | 1.00 | RXFP1 (0.52) | RXFP1AHRMEN1KMT2APHGDH | |
| SCHEMBL13151478 | 0.85 | USP30 (0.56) | RXFP1AHRMEN1KMT2AUSP30 | |
| SCHEMBL10112550 | 0.85 | USP30 (0.56) | RXFP1AHRMEN1KMT2AUSP30 | |
| SCHEMBL14817845 | 0.71 | RXFP1 (0.56) | RXFP1AHRMEN1KMT2APHGDH | |
| SCHEMBL1253301 | 0.70 | RXFP1 (0.72) | RXFP1AHRMEN1KMT2APHGDH | |
| SCHEMBL15045011 | 0.69 | RXFP1 (0.46) | RXFP1AHRMEN1KMT2APHGDH | |
| SCHEMBL2276515 | 0.68 | CHRNA7 (0.61) | MEN1KMT2ACHRNA7HDAC1 | |
| SCHEMBL31264257 | 0.67 | AHR (0.60) | RXFP1AHRMEN1KMT2APHGDH | |
| SCHEMBL15045075 | 0.66 | F10 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419408-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| WO-2010119984-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | IDO1, TPH1, AHR | RXFP1 686/4885AHR 3/4885MEN1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.